Hepatocellular carcinoma-related gene targeting using the large circular antisense library

Oncology Reports

Volumn 20, Issue 4, 2008, Pages 905-911

  Doh, Kyung Oh ^a,b  

^a Dongguk University College of Medicine   (South Korea)

^b Yeungnam University College of Medicine   (South Korea)

Author keywords

fetoprotein; Eukaryotic translation initiation factor 3; Hepatocellular carcinoma; Huh 7 cells; Large circular antisense; Subunit E interacting protein

Indexed keywords

ALPHA FETOPROTEIN; ANTISENSE OLIGONUCLEOTIDE; FLUOROURACIL; INITIATION FACTOR 3; INITIATION FACTOR 3 SUBUNIT E INTERACTING PROTEIN; LARGE CIRCULAR ANTISENSE OLIGONUCLEOTIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE G1 PHASE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG RESEARCH; GENE EXPRESSION; GENE IDENTIFICATION; GENE LIBRARY; GENE SEQUENCE; GENE TARGETING; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOLECULAR CLONING; MONOTHERAPY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; UNINDEXED SEQUENCE;

ANTISENSE ELEMENTS (GENETICS); CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; FLUOROURACIL; HUMANS; LIVER NEOPLASMS;

EID: 54949103137     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or_00000090     Document Type: Article

References (26)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 202. CA Cancer J Clin 55: 74-108, 2005.
2. Hsieh CB, Chou SJ, Shih ML, Chu HC, Chu CH, Yu JC and Yao NS: Preliminary experience with gemcitabine and cisplatin adjuvant chemotherapy after liver transplantation for hepatocellular carcinoma. Eur J Surg Oncol.
3. Mazzanti R, Gramantieri L and Bolondi L: Hepatocellular carcinoma: Epidemiology and clinical aspects. Mol Aspects Med 29: 130-143, 2008.
4. Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet 362: 1907-1917, 2003.
5. Cunningham SC, Choti MA, Bellavance EC and Pawlik TM: Palliation of hepatic tumors. Surg Oncol 16: 277-291, 2007.
6. Lee JS and Thorgeirsson SS: Comparative and integrative functional genomics of HCC. Oncogene 25: 3801-3809, 2006.
7. Kittler R, Pelletier L, Heninger AK, et al: Genome-scale RNAi profiling of cell division in human tissue culture cells. Nat Cell Biol 9: 1401-1412, 2007.
8. Devi GR: siRNA-based approaches in cancer therapy. Cancer Gene Ther 13: 819-829, 2006.
9. Lee YH, Moon IJ, Hur B, et al: Gene knockdown by large circular antisense for high-throughput functional genomics. Nat Biotechnol 23: 591-599, 2005.
10. Silva JM, Marran K, Parker JS, et al: Profiling essential genes in human mammary cells by multiplex RNAi screening. Science 319: 617-620, 2008.
11. Schlabach MR, Luo J, Solimini NL, et al: Cancer proliferation gene discovery through functional genomics. Science 319: 620-624, 2008.
12. Lomnytska M, Dubrovska A, Hellman U, Volodko N and Souchelnytskyi S: Increased expression of cSHMT, Tbx3 and utrophin in plasma of ovarian and breast cancer patients. Int J Cancer 118: 412-421, 2006.
13. Renard CA, Labalette C, Armengol C, et al: Tbx3 is a downstream target of the Wnt/beta-catenin pathway and a critical mediator of beta-catenin survival functions in liver cancer. Cancer Res 67: 901-910, 2007.
14. Jiang WG, Watkins G, Douglas-Jones A, Holmgren L and Mansel RE: Angiomotin and angiomotin like proteins, their expression and correlation with angiogenesis and clinical outcome in human breast cancer. BMC Cancer 6: 16, 2006.
15. Suzuki T, Watanabe K and Ono T: Immunohistochemical demonstration of liver fatty acid-binding protein in human hepatocellular malignancies. J Pathol 161: 79-83, 1990.
16. Liu LL, Gong LK, Qi XM, et al: Altered expression of cytochrome P450 and possible correlation with preneoplastic changes in early stage of rat hepatocarcinogenesis. Acta Pharmacol Sin 26: 737-744, 2005.
17. Hammamieh R, Chakraborty N, Das R and Jett M: Molecular impacts of antisense complementary to the liver fatty acid binding protein (FABP) mRNA in DU 145 prostate cancer cells in vitro. J Exp Ther Oncol 4: 195-202, 2004.
18. Wang XW, Yuan JH, Zhang RG, Guo LX, Xie Y and Xie H: Antihepatoma effect of alpha-fetoprotein antisense phosphorothioate oligodeoxyribonucleotides in vitro and in mice. World J Gastroenterol 7: 345-351, 2001.
19. Lin SB, Huang SS, Choo KB, Chen PJ and Au LC: Inhibition of alpha-fetoprotein production in a hepatoma cell line by antisense oligonucleotide analogues. J Biochem (Tokyo) 117: 1100-1104, 1995.
20. Dong Z and Zhang JT: Initiation factor elF3 and regulation of mRNA translation, cell growth, and cancer. Crit Rev Oncol Hematol 59: 169-180, 2006.
21. Reuter S, Bartelmann M, Vogt M, et al: APM-1, a novel human gene, identified by aberrant co-transcription with papillomavirus oncogenes in a cervical carcinoma cell line, encodes a BTB/POZ-zinc finger protein with growth inhibitory activity. EMBO J 17: 215-222, 1998.
22. Li CF, MacDonald JR, Wei RY, et al: Human sterile alpha motif domain 9, a novel gene identified as down-regulated in aggressive fibromatosis, is absent in the mouse. BMC Genomics 8: 92, 2007.
23. Brummelkamp TR, Bernards R and Agami R: Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2: 243-247, 2002.
24. Fleming JB, Shen GL, Holloway SE, Davis M and Brekken RA: Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. Mol Cancer Res 3: 413-423, 2005.
25. Duxbury MS, Ito H, Benoit E, Zinner MJ, Ashley SW and Whang EE: RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. Biochem Biophys Res Commun 311: 786-792, 2003.
26. Bajpai AK, Park JH, Moon IJ, et al: Rapid blockade of telomerase activity and tumor cell growth by the DPL lipofection of ribbon antisense to hTR. Oncogene 24: 6492-6501, 2005.